Tiapride
Tiapride structure
|
Common Name | Tiapride | ||
|---|---|---|---|---|
| CAS Number | 51012-32-9 | Molecular Weight | 328.42700 | |
| Density | 1.15 g/cm3 | Boiling Point | 498.1ºC at 760 mmHg | |
| Molecular Formula | C15H24N2O4S | Melting Point | 120ºC | |
| MSDS | USA | Flash Point | 255.1ºC | |
|
Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.
Brain 138 , 3221-37, (2015) Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for which there is no effective treatment. Here we provide evidence that activation of serotonergic signalling is beneficial in animal models of Machado-Joseph disease. We ... |
|
|
German insurer finds a third of people over 65 take five or more drugs a day.
BMJ 346 , f3905, (2013)
|
|
|
Pharmacological treatment of tic disorders and Tourette Syndrome.
Neuropharmacology 68 , 143-9, (2013) The present review gives an overview of current pharmacological treatment options of tic disorders and Tourette Syndrome (TS). After a short summary on phenomenology, clinical course and comorbid conditions we review indications for pharmacological treatment ... |
|
|
Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.
Drugs 47 , 1010, (1994) Tiapride, an atypical neuroleptic agent, is a selective dopamine D2-receptor antagonist with little propensity for causing catalepsy and sedation. It shows preferential activity at receptors previously sensitised to dopamine and those located extrastriatally.... |
|
|
Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride.
Eur. Arch. Psychiatry Neurol. Sci. 237(4) , 223-9, (1988) Tiapride, a substituted benzamide derivative, possesses good clinical antidyskinetic properties due to its DA2-blocking activities. It has been shown to be clinically effective in the treatment of tic disease in children. In order to study tiapride's antidysk... |
|
|
Coadministration of L-NOARG and tiapride: effects on catalepsy in male mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry 26(1) , 69-73, (2002) This study was designed to determine the possible potentiation of catalepsy behavior after coadministration of N(G)-nitro-L-arginine (L-NOARG), an inhibitor of nitric oxide synthase (NOS), and tiapride, a specific antagonist for D2 receptors, in male mice. Ca... |
|
|
Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs.
J. Pharmacol. Exp. Ther. 283 , 939, (1997) The RNase Protection Assay was used to examine the regulation of D2 and D4 dopamine receptor mRNAs in the cerebral cortex and neostriatum of nonhuman primates after chronic treatment with a wide spectrum of antipsychotic medications (chlorpromazine, clozapine... |
|
|
Characterization of the discriminative stimulus produced by the dopamine antagonist tiapride.
J. Pharmacol. Exp. Ther. 283 , 566, (1997) The ability of tiapride, a selective D2/D3 dopamine receptor antagonist, to exert discriminative stimulus control of responding was investigated by training rats to discriminate this drug (30 mg/kg) from saline in a two-lever, food-reinforcement procedure. Ac... |
|
|
Transcortical motor aphasia and unilateral parkinsonism in a case of hyperostosis frontalis.
Neurology 80(16) , 1536-7, (2013)
|